Glenmark settles patent case with Daiichi, Genzyme in US

摘要

Glenmark Pharmaceuticals has informed that it has settled a patent infringement litigation with Daiichi Sankyo and Genzyme paving the way for it to market generic colesevelam hydrochloride used for treating diabetes and high cholesterol in the US market. As per the terms of the settlement, the company has received a licence from Daiichi Sankyo and Genzyme that will permit it to launch its generic colesevelam hydrochloride products on April 2, 2015 or earlier under certain circumstances in the US, Glenmark said in a statement.